Over a Decade of Innovation

We are pioneering a new era of medicines
Transforming the lives of patients living with serious diseases


Across a number of disease areas

1

Approved
Therapy

5

Clinical
Programs

10

Preclinical
Programs

First-ever approved crispr-based therapy

CASGEVY™ (Exagamglogene Autotemcel), a CRISPR/Cas9 Gene-Edited Therapy Arising Out of Our Collaboration with Vertex Pharmaceuticals Incorporated, Is Approved in Some Countries for Certain Eligible Patients with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia.

Sign up to the newsletter

Committed to patients

Developing gene-based medicines with the potential to transform the lives of people with serious diseases

Patient Advocacy

Rapidly translating a revolutionary technology into therapies

Innovation that matters

Rapidly translating a revolutionary technology into therapies

Learn more about gene editing
Photo 1680279019882 d0317164a394 1
Learn more about CRISPR-X

Learn more about our programs

We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease.

View Pipeline
Photo 1680279019882 d0317164a394 1 1

Hemoglobinopathies

Aiming to treat sickle cell disease and β-thalassemia with gene-edited blood stem cells.

Learn more
Image 2 3

Immuno-Oncology

Creating the next generation of cell therapies for cancer enabled by gene editing.

Learn more
Getty Images 538032878

Autoimmune

Expanding cell therapies into autoimmune diseases.

Learn more
Getty Images 1441708893

In Vivo

Editing cells inside the body to treat diseases.

Learn more
Getty Images 478945314

Regenerative Medicine

Broadening the applications of stem cells through gene editing.

Learn more

CRISPR Therapeutics Corporate Presentation

View our corporate presentation to learn more about our company.

Download Here